On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year’s event will bring together the leaders in the field from pharma, biotech, Dx companies, and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy, molecular pathology, and precision medicine experts to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as application of liquid biopsy testing, across biofluids, biomarkers and disease indications, as the needle shifts on the gold standard of personalized healthcare testing.
Technological advancements in research on circulating biomarkers from patient-derived blood have enabled a less invasive means of diagnosing non-hematologic cancers. Considered a more practical way of real-time patient monitoring than traditional tumor biopsy, liquid biopsy markers including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and extracellular vesicles (EVs) and exosomes certainly have the potential to change the dynamics of cancer management and treatment.
The BioTech Pharma Summit: Liquid Biopsy 2020 has become an important annual event for leaders in the community to discuss the tools, validation, and implementation of circulating biomarkers, which are transforming our understanding and management of the disease. At the Liquid Biopsy Summit, we will present some recent developments with regards to exosome and ctDNA research and understand the future perspectives on the areas of research for these biomarkers. We believe these non-invasive capabilities and their potential for diagnostic development can influence treatment selections and aid precision cancer therapies.
Conference Website: https://biotechpharmasummit.com/index.php/event/liquid-biopsy-2020/
Venue: Myriad by Sana Hotel
Date: February 20-21, 2020
For more details, please contact:
Email: Diogo.firstname.lastname@example.org | Tel: +351 915 239 640